Different treatments, different minds: The overlooked side of ovarian cancer care

Abstract

Ovarian cancer is not just a serious illness; it also places a heavy psychological strain on patients. In standard care, their mental health is often overlooked. Treatments such as surgery, chemotherapy, targeted therapy, and hormonal interventions come with specific psychosocial challenges. In this editorial, we comment on the study by Wang et al recently published in World Journal of Psychiatry, which found that how psychological adjustment varies greatly among patients, depending on treatment type, disease stage and personal coping skills. Even with improvements in cancer treatment, issues like anxiety, depression, fear of recurrence and body image problems remain major factors affecting quality of life. However, the use of standard psychological assessments in regular ovarian cancer care is still limited. This editorial emphasizes the need to customize psychological support based on treatment types, since mental health outcomes can directly influence adherence, resilience and survival. Tackling the psychological aspects of ovarian cancer requires teamwork among oncologists, psychiatrists, psychologists and palliative care providers. Future research should focus on personalized psychosocial interventions, culturally aware counseling and incorporating mental health care into gynecologic oncology. By understanding that different treatments lead to various psychological effects, we can work toward truly comprehensive ovarian cancer care that values both survival and mental health.

Key Words: Ovarian cancer; Psychological care; Cognitive behavioural therapy; Mindfulness-based stress reduction; Financial toxicity

Core Tip: Ovarian cancer treatments have an enormous impact on the body and mind. Surgery change identity, targeted therapy blends financial stress and hope, and chemotherapy fuels anticipatory anxiety. Multimodal approaches cause the greatest psychological strain, yet they also provide the highest chance for effective and prompt aid. This article argues for culturally sensitive, treatment-tailored and system-adapted psychological care as an important complement to cancer-related advancements, particularly across low-income and middle-income countries, where structural disparities amplify distress.

This editorial refers to "Psychological adjustment differences in ovarian cancer patients receiving different treatment modalities and their clinical significance" by Wang et al, 2025; https://doi.org/10.5498/wjp.v15.i12.111721.

---

INTRODUCTION

Ovarian cancer remains one of the most prevalent gynaecologic malignancies, with around 6.6% of incidence and 4.2% of mortality rates per 100000 women annually. In 2022, approximately 324398 new cases and 206839 deaths of ovarian cancer patients were reported worldwide[1]. Ovarian cancer patients show a poor outcome due to delayed clinical manifestation, high tumor recurrence rate and frequent progression of chemoresistance. Despite significant biomedical advancements over the past decade, including angiogenesis inhibitors, platinum-based chemotherapy, optimal cytoreductive surgery and poly adenosine diphosphate ribose polymerase (PARP) inhibitors, and these advances have not completely altered patients’ overall life experience[2]. Studies found that the overall 5-year survival rate for ovarian cancer patients hovers around 47.4% and most women face recurrence within a few years of initial therapy. Psychological health is a vital part of care, not an extravagance. Depression, anxiety and fear of cancer recurrence (FCR) are highly prevalent in ovarian cancer, the prevalence rates of anxiety and depression are around 33% and 27% during active treatment and survivorship[3]. Beyond emotional turmoil, these symptoms impair adherence, weaken coping ability and disrupt social and family interactions. Untreated psychological distress has an impact on biological processes, with stress-induced activation of neuroendocrine and inflammatory pathways linked with increased tumor progression and lower survival rates[4].

A recent study by Wang et al[5] (retrospective study, n = 286, follow-up was conducted every three months after the initiation of therapy for 24 months) shows how psychological adjustment varies across treatment methods. They have provided valuable data by showing that integrated treatment approaches, such as surgery plus chemotherapy, frequently followed by targeted agents, are linked with higher levels of depression and anxiety, while patients undergoing targeted therapy alone show greater resilience and more adaptive coping. These findings support the growing recognition that the treatment pathway involves not only disease stage, but also independent psychological factors. Studies show that surgery challenges reproductive identity and body image and chemotherapy increase fatigue and anticipatory anxiety, further underscoring the different psychological imprints of each treatment approach[6]. This article calls for a paradigm shift in ovarian cancer care, highlighting that psychosocial support should be systematically tailored and integrated not only to biological and disease-specific aspects but also to contextual factors and treatment approaches. It analyzes the psychological difficulties associated with different treatment types, explores factors that affect adjustment across personal, biological and systemic levels and evaluates the clinical implications for psychiatry and psycho-oncology. Implementation challenges require special attention, especially in low and middle-income countries, where psychological care remains scarce and cultural stigma surrounding mental health is pervasive. Identifying the psychosocial imprint of treatment is therefore a crucial step toward achieving equitable, comprehensive and patient-centered ovarian cancer care.

PSYCHOLOGICAL CHALLENGES ACROSS TREATMENT MODALITIES

Treatment approach in ovarian cancer is more than just a clinical label, it imprints a unique set of psychosocial impacts that influence patients’ thoughts, emotions, social interactions and clinical behavior. The retrospective analysis of Wang et al[5] showed different, modality-specific changes in coping, depression and anxiety, and findings that support the need for treatment-sensitive psychosocial interventions. Particularly, integrated therapy patients showed the highest self-rating depression scale (SDS) and self-rating anxiety scale (SAS) scores and the highest rate of depression and anxiety, while the targeted therapy patients showed the healthiest profile (low depression and anxiety incidence) and the highest positive-coping score. These approach effects were consistent over time and correlated with quality-of-life and adherence metrics in the same patients.

Surgery has an immediate psychosocial impact in ovarian cancer, usually following cytoreductive procedures such as omentectomy, hysterectomy, salpingo-oophorectomy, sometimes bowel resection, or severe peritoneal stripping. The clinical complications, such as loss of fertility, altered genital anatomy, abrupt surgical menopause, scarring and possible persistent pelvic symptoms (urinary or bowel dysfunction, pain, and lymphedema), directly contribute to identity disruption, body image disturbance, partner strain and sexual dysfunction. Prospective multimodal data demonstrate that fertility issues and reproductive loss are associated with long-term distress and sexual morbidity, especially in younger patients who face a rapid, irreversible change in their reproductive capacity. A recent study showed that a 32 years old women had cytoreductive surgery for early-phase ovarian cancer suffered from abrupt loss of fertility and ovarian hormonal function. She reported profound fear about her reproductive identity and future as a young mother with persistent distress about her body and sexual relationship. This clinical scenario demonstrates how fertility anxiety and identity disruption efficiently influence psychological outcomes and highlight the need for pre-surgery psychological approaches that address fertility, sexual function and body image[7,8]. Surgical complications also increase persistent symptom burden. Persistent pelvic symptoms are linked with decreased sexual satisfaction and increased depression[9,10]. According to studies, patients in the surgical cohort showed moderate but significant levels of distress (SDS: 50.2 ± 6.5; SAS: 48.5 ± 6.7), with depression affecting nearly 39% and anxiety nearly 36%. These results indicate that surgery carries a significant psychological burden, even if it is not the highest among treatment approaches[5]. Furthermore, the surgical patients showed recovery signs by month six, suggesting that perioperative psychosocial care aimed at managing menopausal symptoms, body image and sexual rehabilitation could enhance psychological recovery[9,10].

Cytotoxic chemotherapy regimens produce a progressive, rhythmic psychosomatic burden. The recurrent cycle of anticipatory anxiety before treatment, the anticipated beginning of fatigue, nausea, neuropathy and alopecia, along with cognitive challenges, collectively cause a high and persistent distress profile. Empirical studies demonstrate that cancer-related fatigue during chemotherapy acts as a mediator between depressive symptoms and toxicity burden, with higher levels of fatigue indicating subsequent change in function and mood[9]. Cognitive impairment during systemic treatment, usually known as “chemo brain” or cancer-related cognitive impairment, is often reported across all types of cancer and impairs role function and work capacity. Systematic and prospective cohort analysis, including ovarian cancer-specific cohorts, documents objective and subjective impairments in attention, memory and processing speed after chemotherapy and these are linked with decreased self-efficacy and elevated depressive symptoms[11]. Studies demonstrate that chemotherapy patients showed higher depression and anxiety rates than the targeted or surgical treatment patients (SDS: 53.6 ± 7.1; SAS: 52.1 ± 6.9), with a depression incidence rate of around 49.2% and an anxiety incidence rate of around 47.7%. Distress peaked rapidly at month three, aligning with the timing of psychological toxicity and partially subsided by month six. These findings highlight that chemotherapy presents a unique profile (visible markers like alopecia, fatigue-mediated mood alteration, and heightened anticipatory anxiety) that needs frequent, cycle-timed psychosocial therapies and cognitive rehabilitation methods[5,9,11].

Targeted therapy and immunotherapy have become an essential part of many patients’ lives, creating a qualitatively unique psychological response compared to cytotoxic regimens. As a result of these treatments, frequent oral administration, distinct toxicity profiles and representation as precision and next-generation choices, patients usually feel more optimistic, more individualized and more engaged with follow-up. Particularly, a growing perception of PARP inhibitors as relatively acceptable maintenance options has been documented, with extensive narrative and real-world reviews indicating maintenance of health-related quality of life. According to studies, patients with targeted therapy demonstrated the highest scores on positive coping (28.5 ± 3.6) and the lowest rate of depression (31.1%) and anxiety (29.5%), consistent with higher coping self-efficacy in patients receiving precision medicine[5,12]. However, a 48 years old women in a middle-income country receiving PARP inhibitor therapy expressed anxiety and guilt due to high out-of-pocket cost, missed work days for monitoring visits and fear about long-term affordability[13]. This case shows how financial toxicity can undermine the psychological benefits of targeted therapy, emphasizing the need of combining financial counselling and psychological screening. The psychosocial benefit of targeted therapies is conditional, though, as psychological resilience can rapidly weaken by distinct complications (e.g., persistent fatigue or hematologic monitoring requirements), financial toxicity and ambiguity regarding long-term benefits. Current qualitative and health economics work demonstrates that in middle-income regions (e.g., India, Brazil, and South Africa), the financial burden of novel targeted agents often results in catastrophic health spending and a related rise in depression and anxiety among patients and caregivers. As a result, the psychosocial advantages of the targeted therapy seen in clinical trials may not translate in situations where access and funding are lacking[14].

Hormonal treatments present a unique set of psychosocial factors that are usually neglected in the treatment of ovarian cancer, whether they are employed as adjuvant alternatives in certain molecular sub-types, as part of the treatment process for low-grade serous ovarian cancer or for endocrine influence during risk-reducing salpingo-oophorectomy. The principal mechanisms influencing psychosocial alteration and mood are abrupt progestogen/estrogen changes, sexual dysfunction (dyspareunia, vaginal dryness), vasomotor symptoms, sleep disturbance and the cognitive impacts linked with hypoestrogenism. According to recent studies, integrated approaches decrease menopausal and mood symptoms after risk-reducing salpingo-oophorectomy, enhancing emotional control and quality of life. Because hormonal treatments are persistent and less acutely toxic than chemotherapy, their psychosocial impacts can be chronic and insidious. Persistent hypoestrogenic symptoms can weaken interpersonal intimacy, cause body-image issues and trigger low-grade depressive syndromes that lower adherence and behavior related to seeking medical attention[10,15].

Integrated treatment causes a significant cumulative burden, sometimes referred to as a “no-recovery” pattern. The study by Wang et al[5] found that patients undergoing multimodal therapies faced overlapping complications, such as identity changes after surgery, repeated toxicities from chemotherapy and the continuous ambiguity around sustaining or targeted therapy. Their distress increased around three months and unlike other patients, did not improve by six months. Additionally, they showed the highest risk of poor treatment adherence. They reported the worst psychosocial scores (SDS = 58.4; SAS = 56.3), with a depression rate of almost 62.2% and an anxiety rate of around 58.5%. They gained most of the advantage from an 8-week structured psychological intervention, with anxiety rates decreasing by more than 30.5% after the intervention. This “no-recovery” pattern appears correlated to the cumulative symptom burden, increased existential distress and more advanced disease, mostly the International Federation of Gynecology and Obstetrics (FIGO) stage III-IV, highlighting the requirement for substantial and persistent psychosocial care, symptom management and social or financial advice. The distribution of FIGO stages differed minimally across the treatment groups, such as surgery group FIGO I-II 40%, III-IV 60%; chemotherapy group I-II 38%, III-IV 62%; targeted therapy I-II 35%, II-IV 65% and combination therapy I-II 30%, III-IV 70%, these stage ratios were included in the multivariate model to account for any confounding effects on treatment adherence, confirming that the observed differences in treatment adherence and psychological outcomes reflect treatment-specific rather than completely stage-associated impacts[5]. Synthesis and clinical inference emphasize two major requirements across treatment approaches. First is assessment, routine screening at critical points (e.g., before surgery, during chemotherapy cycles, at the beginning and continuation of targeted therapy and again at three and six months) helps to detect distress early. Second is tailoring, treatment should match the primary challenges of each treatment process. Patients undergoing surgery may benefit from body image and sexual rehabilitation, chemotherapy may benefit from cancer-related cognitive impairment care and fatigue management, along with cycle-timed cognitive-behavioral therapy (CBT) or pacing methods, patients undergoing targeted therapy may benefit from ongoing monitoring and financial counseling and patients on endocrine regimens may benefit from hormone replacement therapy and psychosexual support. These approaches are supported by growing randomized and empirical evidence that mindfulness-based stress reduction (MBSR), CBT and quick supportive psychotherapy decrease distress, develop coping and enhance adherence in oncology settings[11,16]. Finally, it is important to identify that treatment impacts are altered by social factors (e.g., rurality, poverty, and health-system capacity), cultural norms (e.g., family caregiving system and stigma) and access factors (e.g., drug coverage and availability of psycho-oncology specialists). While the psychosocial benefits of targeted therapy are well documented, their translation is highly context-dependent. In low and middle-income countries, catastrophic expenses can offset these gains, making scalable alternatives like digital MBSR or nurse-delivered CBT particularly valuable[15,17,18]. According to a recent international survey of 283 psycho-oncology experts from 37 countries, where 40% from the low and middle-income countries found that approximately 26% of respondents in low and middle-income countries reported routine access of distress screening and psychological support services compared to 39% in high-income countries. A global study reported that low and middle-income country respondents were far more likely to recognize the lack of psychological guidelines (77% vs 50%) and guideline implementation (78% vs 56%) as significant challenges compared to high-income country. These findings show that structural differences in service provision are not only theoretical but also show up as quantifiable variations in the accessibility and quality of psychological care across economic settings. Therefore, it is efficient to understand that in areas with insufficient service systems, the psychological advantageous that targeted therapies seem to provide in clinical trials may be reversed or diminished[19,20].

DETERMINANTS OF PSYCHOLOGICAL ADJUSTMENT

Disease stage is one of the best predictors of psychosocial effects in ovarian cancer. Advanced FIGO stage (III-IV) is often linked with increased hopelessness, anxiety and lower health-related quality of life compared to the early stage[21]. Despite therapeutic potential, surveillance biomarkers like carbohydrate antigen 125 usually act as psychological stimulation, causing spikes in fear of recurrence due to catastrophic perceptions of alterations[22]. The retrospective study by Wang et al[5] demonstrated that patients with terminal-stage disease and increased carbohydrate antigen 125 had substantially higher SDS and SAS scores, indicating the prognostic correlation between biological and psychological burden. Resilience and coping abilities determine whether patients adapt or succumb to distress. Active approaches such as acceptance, problem-solving, reframing and social support are usually linked with developed adherence and decreased depression. According to studies, elevated positive coping scores on the patient adjustment to cancer scale indicate better psychological outcomes and adherence. Rumination, denial and avoidance highly predict persistent distress. Studies show that resilience is modifiable, MBSR and resilience training decrease depression and increase coping flexibility in gynecologic cancer patients[16,23].

Adjustment with ovarian cancer is inherently interconnected, with psychological trajectories being cooperatively influenced by families, communities and health systems. Although family members are usually the principal providers of both emotional and instrumental support, they can also cause psychological trauma, which can increase distress and impair coping by carrying on practical strain and anxiety to patients. Studies conducted in low and middle-income countries demonstrated high levels of patient distress and caregiver burden. A cross-sectional study from a tertiary hospital in rural Bangladesh found that depression and anxiety were highly prevalent among cancer patients undergoing chemotherapy and it also detected that family and household factors correlated with psychological conditions[24,25]. In many low and middle-income countries, informal caregivers face substantial emotional and financial burden. A recent study from Southeast Nigeria reveals that increased caregiving burden and reliance on informal coping mechanisms in the absence of formal care services, with financial burden and overload of duties often reported as the major cause of caregiver distress. These caregiver burdens are linked with poorer patient outcomes and decreased ability to provide continuous psychological care[26,27]. In many Western high-income countries psychosocial approaches tend to emphasis individual counselling models instead of family-systems based approaches and studies indicate that individual structured approaches delivered one-to-one or remotely showed more consistent impacts on depression, anxiety and improve quality of life than non-targeted family-group approaches. On the other hand, in many Asian countries the evidence shows the significance if brief family-involved counselling incorporated with palliative or oncology services, reflecting collectivist cultural norms of family decision-making and support. Thus, a comparative cultural analysis suggests that the significance gap between family-involved approaches in Asia and individual approaches in Western countries is efficient and psychological adjustment programmes must adapt culturally to gain optimal outcomes[28-30]. Integrated psycho-oncology interventions are still not consistently adopted at the health system level globally. Compared with high-income countries, distress screening and survivorship focused psychosocial support are less available and implemented in low and middle-income countries. Although incorporating rapid tools (e.g., the distress thermometer) into clinical processes improves need detection, implementation rates and downstream referrals vary significantly across regions[19,31]. In contrast, many high-resource settings have stronger systematic methods for screening and referral for distress. Clinical practice guidelines by the national comprehensive cancer network for distress management recommend stepped referral and routine screening, as well as quality development programs in comprehensive cancer centers have boosted detection and referral to psychological care, where funding allows. However, even in high-income settings, there are still gaps between access and screening to specialized care[32]. Strategies that actively include networks of family members or caregivers have potential across settings. According to studies, family-focused and couple-based psychological programs in Europe and other countries reduce the burden on caregivers and improve patients’ quality of life. Asian feasibility studies reveal that brief family counselling embedded in palliative services or oncology care can reduce patient and family distress, but larger, multi-site trials are still needed to determine effectiveness and scalability in low and middle-income countries[33].

Cultural norms and socioeconomic status have significant, interconnected effects on psychological adjustment to ovarian cancer. Cancer is frequently experienced and treated as a family illness, but the stigma shared with mental health and illness-related shame deters people from disclosing and seeking help, which enhances under recognized psychological morbidity[34]. Research demonstrates that in sub-Saharan Africa, cost-driven interruptions of chemotherapy and care elevate psychiatric burden and demoralization. In South Asia and other low and middle-income countries, elevated rates of financial hardship are strongly correlated with psychological distress. Financial toxicity, determined as catastrophic expense spending, debt or treatment delay, continuously indicates poorer quality of life and increased levels of depression and anxiety across countries[35-37]. Even in cases where public coverage and formal insurance exist, survivorship requires and access to targeted systemic therapies can impose large residual expenses and financial burden, which is linked with psychological distress among ovarian cancer patients[13]. Health-system-related challenges compound these personal and family drivers, such as low and lower-middle-income countries typically have extremely limited mental-health work forces (often below one psychiatrist per 100000 individuals), weak referral processes and few integrated psycho-oncology assistance. These factors together make it more challenging to detect distress and provide evidence-based psychological care on an extensive scale[38]. Socioeconomic gradients also have an impact in high-income countries, as national data from China demonstrates clear rural-urban gaps in health-care utilization and accessibility to psychological care, while other studies reported that persistent links between lower household income and limited accessibility to psychological care and higher unmet psychological requirements despite increased service availability[39,40]. When combined, these lines of evidence demonstrate that cultural norms, financial toxicity, access disparities and structural workforce work together to influence psychological responses in ovarian cancer. As a result, culturally adapted models that combine routine brief distress screening, task-sharing with non-specialist healthcare professionals, caregiver-related treatments and particular mechanisms to detect and mitigate financial hardship as significant components of equitable psycho-oncology implementation are increasingly important[13,34,38].

CLINICAL IMPLICATIONS FOR PSYCHIATRIC CARE

Implementing an efficient psychiatric/psycho-oncology approach requires simultaneous focus on workforce, assessment and system-level interactions. Routine screening must be integrated into care approaches that specify who acts on positive outcomes, when and how they do so (Table 1)[5,41-52]. According to guidelines, screening alone is not sufficient unless it influences stepped approaches and monitoring of process parameters like time-to-initial intervention, equity of reach, screening coverage and fidelity. Multimodal psychological initiatives that integrate mindfulness training, cognitive-behavioral aspects and encouraging group processes produce adherence advantages and reproducible signs in cancer patients and their effectiveness can be utilized to power pragmatic trials, where workforce shortages are present, supervised work-sharing (e.g., nurse or community-health-staff provider with specialized supervision) and digital/telehealth techniques are evidence-backed scalability modalities. Financial and equity assessments (e.g., stratified reach assessment, cost-effectiveness, and cost-per-quality-adjusted-life-year) needed to be incorporated in low and middle-income countries to assist policy translation[5,49,51,53].

Table 1 Validated psycho-oncology screening tools and recommended referral pathways.

Tool/instrument	Purpose and setting	Administration period/items	Common cut-off(s)	Referral pathway/recommender immediate action	Key evidence and notes	Implementation barriers	Ref.
Notes for local adaptation	Translate and culturally adapt tools; pilot test acceptability	Cognitive testing and brief pilot	Transparent adaptation with translation, testing and piloting that confirms credibility uptake	Include caregiver modules and measure caregiver burden	Cultural framing enhances uptake; family-inclusive work addresses caregiver distress parallel to patient outcomes	High-income: Language and cultural fit well supports. Low/middle-income: Need translation, piloting and cultural adaptation before rollout	[5]
Delivery models	Scalability options for low and middle-income countries/rural areas	Nurse-delivered brief CBT, digital/telehealth CBT, group MBSR	N/A (model selection based on resources)	Use stepped-care matching patient severity to intervention intensity; plan supervision and fidelity checks	Task-sharing and telehealth demonstrate feasibility and efficiency in psycho-oncology and low and middle-income countries adaptation literature	High-income: Multidisciplinary teams available. Low/middle-income: Depend on nurse-led or telehealth models; training gaps common	[51,52]
PHQ-9	Depression screening across oncology settings (e.g., survivorship clinics, outpatient)	About 2 minutes to 5 minutes self-report or clinician-administered; 9 items	Typical threshold: ≥ 10 (moderate). Local program may use ≥ 10/≥ 15 for stepped care. Sensitivity 63% and specificity 77% in cancer populations	Positive: Brief psychological triage within 24 hours; PHQ-9 ≥ 10: Enroll in brief digital CBT/CBT or nurse-led program within 72 hours; PHQ-9 ≥ 15 or suicidal idea: Urgent psychiatric evaluation and safety plan within 24 hours	Two-step screening feasibility/validation in cancer, including PHQ-9 performance. Validated in oncology/ovarian cancer cohorts	High-income: Quick access to psychologist within 72 hours. Low/middle-income: Few specialists; nurse-led triage or remote consultation may take 1-2 weeks	[41]
GAD-7	Screening for generalized anxiety and panic symptoms during treatment and follow-up	About 2 minutes to 5 minutes; 7 items	≥ 10 indicates clinically efficient anxiety. Sensitivity: 25% to 77.8% and specificity 86.5% to 95.4%	GAD ≥ 10: Provide targeted psychological therapy (CBT/MBSR) within 7 days, monitor and escalate to psychiatry if chronic or comorbidities	Diagnostic accuracy and feasibility assessments of GAD-7 in cancer patients. Validated in oncology settings	High-income: Individual CBT available within 2 weeks. Low/middle-income: Often depend on short counseling or dig CBT; longer waits times	[42,43]
FCRI-SF	Focused screening for FCR at transition stages and survivorship	About 3 minutes to 5 minutes; short-form (severity sub-scale) about 9 items	Apply validated cut-points from validation studies; use established threshold validation to detect clinically efficient FCR (use local validation). Sensitivity: 90%; specificity: 83.3%	Positive/high score: Referral to FCR-focused CBT or short FCR group intervention; consider psycho-education and family involvement	Recent large-sample work validating FCRI-SF screening ability and prevalence. Validated in oncology settings	High-income: Structured FCR program exist. Low/middle-income: Use brief group or online sessions due to limited trained experts	[44,45]
NCCN distress thermometer and problem list	Fast triage across clinics; international translations available for worldwide application	< 2 minutes; single 0-10 thermometer and problem checklist	Score ≥ 4 or local threshold. Sensitivity: 100%; specificity: 72.3%	Score above threshold: Problem-driven referral pathway (e.g., palliative care, psychiatry, psychology, and social work) within 72 hours	Recent decision tree validation and update studies in breast/other cancer studies. Validated in gynaecologic cancer settings	High-income: Fast referral to psychosocial staff. Low/middle-income: Limited staff; use brief counseling or phone follow-up instead	[46,47]
EORTC QLQ-C30	Comprehensive QOL measurement for program assessment and trials	5-8 minutes, used as an outcome measure rather than a fast screen; 30 items	Not a screening tool; use for baseline and result evaluation in trials	Use as a secondary result for psychological intervention trials and to measure functional alteration	Gold standard QOL measure in oncology trials; recommended for trial endpoints	High-income: Used routinely for trials and audits. Low/middle-income: Limited use due to staff workload and data-entry complications	[48]
Operational items/implementation	Stepped-care linkage and system readiness	Track: Screening coverage, fidelity, uptake, time-to-intervention, and cost per patient	Pre-specified targets (e.g., > 80% screening coverage; time-to-intervention < 2 weeks)	Required: Named psychological lead, referral protocols, and supervision plans for task-sharing employees	Implementation parameters align with guideline recommendations and the implementation science framework	High-income: HER systems permit rapid monitoring. Low/middle-income: Manual monitoring; less trained staff cause delays	[49,50]

PHQ-9: Patient Health Questionnaire-9; CBT: Cognitive-behavioral therapy; N/A: Not applicable; GAD-7: Generalized Anxiety Disorder 7-item; MBSR: Mindfulness-based stress reduction; FCRI-SF: Fear of cCancer Recurrence Inventory-Short Form; FCR: Fear of cancer recurrence; NCCN: National Comprehensive Cancer Network; EORTC QLQ-C30: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; QOL: Quality of life.

BRIDGING THE GAP: RECOMMENDATIONS FOR PRACTICE

Psychological support for patients with ovarian cancer needs to be tailored to the psychosocial characteristics of the treatment process, because observational and randomized work in gynecologic oncology shows that different approaches (e.g., cytotoxic chemotherapy, surgery, targeted maintenance, multimodal sequences and endocrine regimens) generate distinct clusters of functional impairment, distress, cognitive symptoms and identity/sexual concerns that react differently to targeted therapies. Cognitive-behavioral methods decrease anxiety, depression, fatigue and fear of recurrence across clinical trials in gynecologic oncology. They represent a general first-line approach, but must be targeted (e.g., cognitive rehabilitation and fatigue pacing during chemotherapy; body image and psychosexual modules after cytoreductive surgery; financial stress/adherence counselling around targeted agents)[54]. Studies reveal that the need for an intervention strategy addressing FCR, sexual dysfunction and existential distress as distinct objectives rather than depending on generic “distress” responses alone[23]. Practical implementation requires routine, stepped screening at predetermined decision stages (e.g., pre-operation, every chemotherapy cycle, at the onset of maintenance therapy and at 3-6 months follow-up). Clear, geographically feasible referral strategies are also required so that positive screens trigger defined interventions rather than only documentation. According to the national comprehensive cancer network distress management guidance and the current two-step screening validations highlight that screening without a defined stepped response fails to develop outcomes, programs must set thresholds, rapid triage stages and time-to-initial treatment goals[49,41]. In low and middle-income countries, where professional psycho-oncology ability is limited due to workforce constraints, catastrophic expenses and stigma mean that tailored models need to be explicitly integrated with low-intensity psychological lessons, caregiver-inclusive sessions and financial guidance with expert referral for complicated cases. High financial toxicity and catastrophic expenses from cancer treatment in low and middle-income countries cause and increase psychosocial morbidity and therefore require being part of personalized psychosocial plans for those on expensive targeted or maintenance regimens[55,56].

Studies demonstrate that CBT and related cognitive-behavioral methods (e.g., problem-solving and metacognitive variants) generate clinically significant improvements in fatigue, FCR, anxiety and depression among gynecologic cancer patients and they should serve as the fundamental component of psychosocial programs for patients with ovarian cancer, when associated with symptom categories[54]. FCR, particularly manualized, values and metacognitive programs provided in groups or online (e.g., conquer fear variations) have shown moderate impact size in clinical trials and can be provided remotely with fidelity checks[57]. Mind-body and mindfulness-based approaches, such as brief MBSR adaptations, have shown positive impacts on resilience and distress in cancer patients; these are also appropriate adjuncts for patients with sleep disturbance, persistent distress or treatment-related hypervigilance. These interventions can be incorporated into CBT frameworks like mindfulness-informed CBT, when preferred by patients[54,57]. Digital platforms, such as guided online CBT, standalone apps and structured mobile programs, have now been experimented with in gynecologic cancer patients and exhibit moderate to significant improvements in distress and depression while efficiently developing reach. Clinical trials of mobile structured and support app programs like the mobile gynecological cancer support program and the WeChat-based CBT trial report developing uncertainty, quality of life and symptom distress compared to usual care[58,59]. To translate these significant data into low and middle-income country practice, implementation needs to address digital equity (e.g., bandwidth/device constraints), cultural adaptation (e.g., idiom of distress, language), supervision and fidelity through task-sharing and measurable quality assurance. Task-sharing and stepped support methods have continuous evidence for feasibility and efficiency across resource-constrained settings and are an implementation priority where there is a shortage of psychologists and psychiatrists[60].

Psycho-educational programs that include family or caregivers to dispel misconceptions, increase practical caregiving skills, reduce stigma, and therefore must be a significant part of ovarian cancer psychological programs, especially where family regulates treatment accessibility and adherence. Caregiver and community education programs in low and middle-income countries decrease caregiving misconceptions and improve readiness for treatment-related care chores, with quantitative implications on patient adherence and caregiver burden[61,62]. The high prevalence of identity distress and sexual dysfunction after ovarian cancer treatment, psychosexual education like partner-inclusive counseling, particular psychosexual rehabilitation methods and communication skill training are evidence-supported and ought to be provided as routine survivorship support rather than as a one-time referral. According to systematic assessments, psychological sexual-health approaches improve at least a few areas of sexual function and satisfaction in pelvic cancer survivors[23,63]. Counseling must also cover navigation and financial toxicity, such as explaining expected expenses, insurance choices and available social support, because financial toxicity is a significant, treatable reason for psychological distress in low and middle-income countries[55]. Practically, patient and family counseling programs ought to be provided through various channels like video modules, low-literacy leaflets, short bedside counseling and mobile apps and should be implemented with cognitive testing to confirm cultural acceptability. Randomized trials conducted in China and other middle-income countries show that video-based and mobile supportive care lessons can enhance quality of life and reduce anxiety and uncertainty with routine oncology support[58,64].

CONCLUSION

Ovarian cancer has advanced efficiently with surgery, chemotherapy, targeted therapies and hormonal regimens by improving survival. Yet, the story of survival is incomplete if psychological survival resilience, coping and quality of life are overlooked. Effective care must therefore integrate disease survival with psychological health survival as complementary and interdependent goals. The study by Wang et al[5] demonstrates that treatment modality itself is a determinant of psychological trajectory. Surgical patients struggle with body-image alteration and reproductive identity loss, chemotherapy patients experience fatigue and anticipatory anxiety, targeted therapy patients manage optimism and financial strain and multimodal patients endure cumulative “no-recovery” distress. Interestingly, patients receiving targeted therapy showed better psychological adjustment and higher treatment adherence, whereas nearly two-thirds of multimodal patients had the lowest adherence and clinical depression or anxiety. These findings show the close connection between biological and psychological outcomes. Clinical translation needs three agreements. First, routine screening for distress must be implemented at defined stages, before surgery, during chemotherapy cycles, at the beginning of targeted rehabilitation and in survivorship follow-up. Screening alone is insufficient; it must influence stepped, time-bound responses. Second, interventions need to be treatment-tailored, such as body image and psychosexual rehabilitation after surgery, cycle-timed CBT and cognitive rehabilitation during chemotherapy, financial counselling alongside targeted therapy and long-term psychosexual support during the endocrine treatment process. Third, scalable distribution methods are essential, such as task sharing with community or nurse workers in low-resource settings, digital CBT platforms in middle-income settings and family-inclusive counselling in cultures where caregiving determines treatment access. Interventions can improve treatment adherence by 22.7% and can reduce anxiety incidence by over 30% in multimodal patients, demonstrating that psychological survival is clinically significant and alterable. According to recent studies, in ovarian cancer patients, evidence ensures a significant gap, where psychosocial and psychological interventions are showing effective short-term advantages, almost all studies identify outcomes only up to 6 months, with very few reporting or extending quality of life outcomes beyond 12 months. Health and policy systems need to transition from aspiration to accountability. Quality frameworks should include psychological indicators like time-to-intervention, screening coverage and quality of reach. In low and middle-income countries, financial strain is linked with psychological burden, demanding that psycho-oncology be integrated with financial navigation and social support. Without system-level accountability, psychosocial care risks remaining optional rather than necessary. Future studies need to pursue three directions. First, mechanistic studies should elucidate the manner in which distress alters inflammatory and neuroendocrine pathways, therefore reaffirming the correlation between biological and psychological survival. Second, precision psycho-oncology trials are required to assess whether treatment-modality-specific interventions function better than generic approaches. Third, implementation science must drive adaptation to various realities, such as low-literacy education in South Asia, telehealth CBT in rural China and caregiver-inclusive models in Africa. Additionally, research could explore the use of artificial intelligence assisted psychological screening instruments at the primary care level to enable customized intervention, early detection and scalable monitoring of psychological distress. Evidence of feasibility, cost-effectiveness and fidelity will be crucial for scale-up. The upcoming decade must redefine what success in ovarian cancer treatment means. A patient who survives longer but endures relentless depression, anxiety or identity loss has not achieved true survival. On the other hand, patients who receive psychological care may improve biological resilience besides adhering to treatment more consistently. Comprehensive survival, therefore, requires a dual lens-one that treats tumor biology while protecting psychological integrity.